Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and ...

Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American ...

Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of ...

German biosimilar manufacturer STADA Arzneimittel reported a 9% revenue increase in the first half of 2024, with over €2 ...

Sarfaraz K. Niazi, PhD, explains the FDA's new guidelines on post-approval changes for biosimilars, emphasizing the processes ...

A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority ...

While biosimilars could potentially lower costs and improve access to gene therapies, significant hurdles in regulation, ...

A study found patients with neovascular age-related macular degeneration (nAMD) successfully switched from aflibercept to the ...

Switching children with juvenile idiopathic arthritis (JIA) from anti-tumor necrosis factor (TNF) originators to biosimilars ...

Number 5: With the end of the second quarter comes expense reports, new biosimilar business deals, and insights into how ...

Ivo Abraham, PhD, RN, University of Arizona Cancer Center, urges stakeholders to provide patient advocacy groups with ...

Patients with rheumatoid arthritis who switched from the etanercept originator to a biosimilar exhibited similar disease ...